Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial (Q33430055)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial |
scientific article |
Statements
1 reference
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial (English)
1 reference
Katherine K Matthay
1 reference
John M Maris
1 reference
Steven G DuBois
1 reference
Araz Marachelian
1 reference
Elizabeth Fox
1 reference
Rachel A Kudgus
1 reference
Joel M Reid
1 reference
Susan Groshen
1 reference
Jemily Malvar
1 reference
Rochelle Bagatell
1 reference
Lars Wagner
1 reference
Randall Hawkins
1 reference
Jesse Courtier
1 reference
Hollie Lai
1 reference
Fariba Goodarzian
1 reference
Hiroyuki Shimada
1 reference
Scarlett Czarnecki
1 reference
Denice Tsao-Wei
1 reference
Yael P Mosse
1 reference
16 February 2016
1 reference
1 reference
34
1 reference
12
1 reference
1368-1375
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference